title: Tubulin-targeting agent combination therapies: dosing schedule could matter.
abstract: Tubulin-binding agents are potent cytotoxic drugs that are largely used to treat haematological malignancies and solid tumours. In this issue of British Journal of Pharmacology, doxorubicin was shown to decrease the activity of vincristine when administered simultaneously, unless cell cycle arrest mechanisms were disrupted. This observation emphasizes the need to better explore schedule-dependent antagonist effects in anticancer drug combination therapies.
  
  
  BACKGROUND
  This article is a commentary on the research paper by Ehrhardt et al., pp. 1558-1569 of this issue. To view this paper visit http://dx.doi.org/10.1111/bph.12068.
authors: Institut Gustave Roussy, Villejuif cedex, France. eric.solary@igr.fr
authors: Eric
authors: E
authors: Solary
mesh_terms: D000818:Animals; D018943:Anthracyclines / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology*; D005260:Female; D006801:Humans; D014750:Vincristine / Q000494:pharmacology*
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D014750:Vincristine; D003907:Dexamethasone